Application of PSMA PET/CT Specific Molecular Imaging in Diagnosis of Non-prostate Cancer
-
摘要:
前列腺特异性膜抗原(PSMA)是由前列腺上皮细胞分泌的一种Ⅱ型谷氨酸缩肽酶,特异性高表达于前列腺癌及其转移灶的细胞中,在多数实体瘤部位毛细血管内皮细胞中有较高程度的表达。目前,已有超过二十种PSMA靶向的分子探针用于前列腺癌的诊断与治疗。本文综述了PSMA在除前列腺癌以外的多种实体瘤中的表达情况及PSMA-PET/CT特异性探针在非前列腺癌诊断中的临床应用实例,以期拓展以PSMA为靶点的新型PET探针在肿瘤分子诊断中的临床应用。
-
关键词:
- 前列腺癌特异性膜抗原 /
- PET/CT /
- 非前列腺癌
Abstract:Prostate specific membrane antigen(PSMA) is a glutamate carboxypeptidase Ⅱ secreted by the epithelial cells of prostate gland. PSMA is over-expressed in the cells of prostate cancer and metastases, and also positively expressed in the tumor-related neovascular endothelial cells. Therefore, more than twenty PSMA-targeted probes had been used for the diagnosis and therapy of prostate cancer. This article reviews the expression of PSMA in non-prostate cancer and the clinical application of PSMA-PET/CT specific probes in detecting non-prostate cancer, to expand the clinical application of novel PSMA-targeted PET probes in the diagnosis of tumors.
-
Key words:
- Prostate specific membrane antigen(PSMA) /
- PET/CT /
- Non-prostate cancer
-
0 引言
胶质瘤是中枢神经系统最常见的颅内原发恶性肿瘤,在所有颅内原发性肿瘤中占70%左右,其中成年人中最常见、恶性程度最高、预后最差的肿瘤是胶质母细胞瘤(glioblastoma, GBM, WHO Ⅳ)[1]。该肿瘤具有恶性增殖和高侵袭性的特点,手术及放化疗后肿瘤复发率高。
JNK/c-Jun信号通路在调控细胞增殖、分化、凋亡和存活等基本生物学效应中扮演重要角色。JNK磷酸化下游底物c-Jun并使其激活后,可增强肿瘤细胞的增殖、侵袭和迁移能力[2-4]。MKK4和MKK7作为丝裂原活化蛋白激酶激酶(mitogen-activated protein kinase kinase, MAPKK)家族的两个成员,均可以磷酸化并激活JNK[5-7]。有报道称MKK7通过调控JNK活性调控细胞凋亡[8-10]。本课题组前期研究也发现在神经胶质瘤细胞株U251中,小分子干扰沉默MKK7表达后,可以抑制JNK/c-Jun激活[11]。为进一步了解JNK信号通路的调控机制,本研究通过采用免疫组织化学法、小分子干扰、转染及Western blot等技术检测不同组织学类型胶质瘤样本及U87细胞株中MKK7、c-Jun及其磷酸化的表达情况,分析并验证MKK7是否为直接调控JNK/c-Jun活性的关键分子。
1 资料与方法
1.1 资料
收集2015年11月—2017年11月广州医科大学附属第二医院病理科存档的胶质瘤石蜡包埋标本117例,其中92例胶质瘤和25例胶质母细胞瘤瘤旁正常脑组织。按2016年版“WHO中枢神经系统肿瘤的病理分类”,92例胶质瘤中:WHOⅡ:弥漫型星形细胞瘤15例,少突胶质细胞瘤5例;WHOⅢ:间变性星形细胞瘤11例,间变性少突胶质细胞瘤8例;WHOⅣ:胶质母细胞瘤53例(仅25例有相应的正常对照),患者临床病理特征见表 1。所有患者术前均未行放化疗,均知情同意。本研究得到医院医学伦理会审核批准。
表 1 92例胶质瘤患者临床病理特征Table 1 Clinicopathological features of 92 gliomas patients人脑胶质瘤U87细胞株购自上海细胞生物学研究所中国科学院细胞库。胎牛血清、0.25%胰酶购于美国Gibco公司。培养基高糖DMEM、转染试剂RNAi MAX、opti-MEM reduced serum medium均购于美国Invitrogen公司。MKK7-1 siRNA、MKK7-2 siRNA、MKK4 siRNA、空白对照siRNA购自上海Gene Pharma公司。anti-MKK7(#4172)、anti-MKK4(#9152)、anti-p-c-Jun(#3270)、anti-GAPDH(#2118s)均购于美国Cell Signaling Technology公司。anti-c-Jun(sc-74543)购美国Santa Cruz Biotechnology公司。
MKK4-siRNA小分子片段序列正义链:5’-GCCUUACGAAGGAUGAAUCCATT-3’,反义链:5' -UGGAUUCAUCCUUCGUAAGGCTT-3’;MKK7-siRNA1小分子片段序列正义链:5’-CCAACACGGACGUCUUCAU-3’,反义链:5’-AUGAAGACGUCCGUGUUGG-3’;MKK7-siRNA2小分子片段序列正义链:5’-GCUGGCAACAGGACAGUUU-3’,反义链:5’-AAACUGUCCUGUUGCCAGG-3’。
1.2 方法
1.2.1 免疫组织化学染色及评判标准
所有石蜡包埋病理标本均经10%中性福尔马林固定,常规HE染色组织学观察。采用Envision二步法进行免疫组织化学染色。检测标志物:MKK7、c-Jun和p-c-Jun。4 μm厚度切片经脱蜡水化和抗原修复后,滴加一抗,放入37℃水浴箱孵育60 min,PBS冲洗后按照采用Envision检测试剂盒(DAKO公司)说明书进行,室温孵育30 min,再次PBS冲洗,DAB显色,苏木精对比染色,然后脱水、透明、封片,每例均设阳性和阴性对照。按照抗体说明书分别用膀胱组织及肺癌组织作为阳性对照,另外用PBS代替一抗作为阴性对照。
免疫组织化学结果半定量判定:染色程度:基本不着色为0分;着色呈淡黄色为1分;着色呈黄色为2分;着色呈棕褐色为3分。染色阳性细胞百分比计数,计算阳性肿瘤细胞占总肿瘤细胞的比例,将其分为5个等级:着色阳性细胞占计数细胞≤5%为0分(-),5%~25%为1分(+), > 25%~50%为2分(++), > 50%~75%为3分(+++), > 75%为4分(++++)。将染色程度分级与染色细胞百分比相乘,乘积≥4分为高表达, < 4分为低表达[12-13]。
1.2.2 细胞培养、转染和Western blot检测
将U87细胞株置于10%胎牛血清、高糖DMEM液体培养液,37℃、5%CO2及饱和湿度条件下培养,每3~5天用胰酶消化传代1次,取对数生长期细胞进行实验。
于6孔板内接种对数生长期U87细胞,细胞密度为2×105个每孔,培养液为不含抗生素的DMEM培养液。待细胞生长至60%~80%融合度时,更换为不含血清的DMEM培养液,12 h后按转染试剂RNAi MAX转染方法将MKK4-siRNA、MKK7-siRNA1、MKK7-siRNA2和空白对照siRNA分别转染入U87细胞。
U87转染细胞于37℃培养箱培养48 h后,每孔2 ml PBS漂洗2遍,每孔加入150 μl IP细胞裂解液(50 mmol/L Tris, HCl pH8.0, 150 mmol/L NaCl, 1%Triton×100, 100 μg/ml PMSF),10 min后收集各组细胞。按照IP裂解液法提取细胞总蛋白,并进行BCA法测定蛋白浓度。灌制4%集成胶和10%分离胶。200 V电压电泳45 min。100 V电压转膜60 min。5%脱脂奶粉室温封闭1 h。一抗(anti-MKK4 1:1 000,anti-MKK7 1:1 000,anti-c-Jun 1:1 000,anti-p-c-Jun 1:1 000,anti-GAPDH 1:5 000)4℃孵育过夜,HRP标记抗兔或抗鼠室温孵育1 h。ECL化学发光后曝光。
1.3 统计学方法
用SPSS20.0统计分析软件包进行数据处理。多组间MKK7及p-c-Jun表达率的比较用多个样本率的χ2检验。数据以平均值±标准差(x±s)表示,多样本间比较采用单因素方差分析One-way ANOVA,两组间的比较采用独立样本t检验。相关性分析采用Spearman等级相关分析。P < 0.05为差异有统计学意义。
2 结果
2.1 c-Jun和p-c-Jun在胶质瘤及胶质母细胞瘤瘤旁正常脑组织中的表达
c-Jun和p-c-Jun阳性表达表现为细胞核内见棕黄色颗粒,见图 1。25例胶质母细胞瘤中3例(12%)c-Jun高表达,其瘤旁正常脑组织中均低表达,两者间差异无统计学意义(χ2=3.128, P=0.077),而胶质母细胞瘤中p-c-Jun高表达19例(76%),明显高于瘤旁正常脑组织6例(4%),差异有统计学意义(χ2=27.000, P=0.000)。胶质母细胞瘤中c-Jun的表达与其他类型胶质瘤无明显差异(P=0.086),但p-c-Jun表达明显升高(P=0.000),见表 2。根据WHO分级,WHO Ⅳ级胶质瘤p-c-Jun高表达率明显高于WHO Ⅱ级及WHO Ⅲ级胶质瘤(P=0.000),见图 2A,且p-c-Jun表达强度与胶质瘤WHO分级呈明显正相关(r=0.494, P=0.000)。
图 1 不同WHO分级胶质瘤及胶质母细胞瘤瘤旁正常脑组织中c-Jun、p-c-Jun、MKK7的表达Figure 1 Expression of c-Jun, p-c-Jun and MKK7 in gliomas with different WHO classification and normal brain tissues adjacent to glioblastomaA-D: c-Jun, p-c-Jun and MKK7 expression in normal brain tissues adjacent to glioblastoma; E-H: oligodendroglioma(WHO Ⅱ); I-L: anaplastic astrocytoma(WHO Ⅲ); M-P: glioblastoma (WHO Ⅳ); A, E, I, M: HE×200; B-D, F-H, J-L, N-P: IHC ×200表 2 不同组织学类型胶质瘤组织中c-Jun及p-c-Jun表达情况Table 2 c-Jun and p-c-Jun expression in different histological types of gliomas2.2 MKK7在胶质瘤及胶质母细胞瘤瘤旁正常脑组织中的表达
MKK7阳性表达表现为细胞核或质内见棕黄色颗粒,见图 1。胶质母细胞瘤中MKK7的表达高于其他类型胶质瘤及胶质母细胞瘤瘤旁正常脑组织(P=0.000),见表 3。且MKK7高表达率随着WHO分级的升高而增加(P=0.000),见图 2A。MKK7表达强度与胶质瘤WHO分级呈明显正相关(r=0.606, P=0.000)。
表 3 不同组织学类型胶质瘤及胶质母细胞瘤瘤旁正常脑组织组织中MKK7表达情况Table 3 MKK7 expression in gliomas with different histological types and normal brain tissues adjacent to glioblastoma2.3 c-Jun磷酸化与MKK7在不同WHO级别胶质瘤组织中的表达及其相关性
92例胶质瘤及25例胶质瘤母细胞瘤瘤旁正常脑组织中,48例MKK7和p-c-Jun均高表达,31例均低表达,30例MKK7高表达和p-c-Jun低表达,8例MKK7低表达和p-c-Jun高表达。根据Spearman相关分析检验,MKK7表达与c-Jun磷酸化水平正相关(r=0.387, P=0.000),见图 2B。
2.4 转染siRNA对MKK4、MKK7表达及c-Jun活性的影响
与空白对照组siRNA相比,U87细胞转染MKK4-siRNA、MKK7-siRNA1和MKK7-siRNA2可分别显著抑制MKK4(P=0.003)和MKK7(P=0.009)表达,但只有转染MKK7-siRNA可同时下调c-Jun磷酸化水平(P=0.004),见图 3。
3 讨论
c-Jun N-末端激酶(C-Jun N-terminal kinase, JNK)属于丝裂原活化蛋白激酶家族,其家族包括JNK1、JNK2和JNK3[14],其中JNK1和JNK2广泛表达于各种组织中,而JNK3主要表达于脑、心脏及睾丸等组织中[15]。JNKs参与许多生理过程,如炎性反应、细胞增殖、分化及死亡,Nacken等[16]研究表明JNK活化可促进流感病毒A(IAV)的非结构蛋白(NS1)的表达,从而诱导细胞的凋亡。而且肿瘤的发生和进展也存在JNKs的持续激活,有研究通过体内或体外实验证明多种恶性肿瘤与JNK/c-Jun的激活密切相关,如胃癌、肝癌、胰腺癌、骨肉瘤、脑肿瘤及结直肠癌等中均存在不同JNK蛋白的高表达或突变[17-20]。本研究基于免疫组织化学方法,探讨胶质瘤中c-Jun的磷酸化水平的表达情况。与正常脑组织及非胶质母细胞瘤相比,胶质母细胞瘤中磷酸化c-Jun的表达明显升高,胶质母细胞瘤的高表达率为81.1%,表明磷酸化c-Jun过表达参与了胶质母细胞瘤的发生与发展。
替莫唑胺(TMZ)是目前公认的治疗脑胶质瘤效果较好的化疗药物,然而脑胶质瘤对TMZ产生耐药性是导致化疗失败的重要原因。因此,为胶质母细胞瘤的化疗寻找新的靶点及新的化疗药物成为了胶质瘤的研究热点。有研究证明在JNK/c-Jun激活后,可以增强替莫唑胺和尼莫司汀等烷化剂等药物对胶质母细胞瘤的促凋亡作用。Tomicic等[21]发现烷基化抗癌药物作用于胶质瘤细胞LN-229后,JNK/c-Jun激活参与了晚期促凋亡反应。Ueno等[22]通过建立耐TMZ细胞模型,与对照组相比,试验组c-Jun终末激酶(JNK)的磷酸化水平增加,其下游信号通路的活性增加。上调JNK表达或siRNA特异性干扰及JNK抑制剂抑制JNK表达可以促进或抑制试验组细胞迁移及侵袭。因此,表明JNK信号通路可能成为新型治疗TMZ耐药胶质瘤的靶点。本研究也进一步证明不同级别胶质瘤c-Jun的表达水平不同,为胶质瘤的化疗,特别是TMZ耐药的处理提供了证据。
JNK/c-Jun通路的激活在胶质母细胞瘤的发生发展过程中起重要作用,但其上游调控机制并不完全清楚。JNK上游有两个MAPKK,即MKK4和MKK7。我们通过小分子干扰的方法沉默胶质瘤U87细胞株中MKK4及MKK7,发现沉默MKK7后c-Jun磷酸化水平明显下调,而沉默MKK4后c-Jun磷酸化水平无明显变化,在细胞学水平证明了MKK7是调控JNK/c-Jun活性及胶质瘤细胞增殖的关键分子。为了进一步探讨MKK7和磷酸化c-Jun的表达在胶质瘤发生发展中的关系。本研究检测了胶质母细胞瘤瘤旁正常脑组织与不同组织学类型及WHO分级的胶质瘤中MKK7和磷酸化c-Jun的表达情况,发现随着胶质瘤WHO分级的增加,MKK7及磷酸化c-Jun的高表达率明显升高;且MKK7及磷酸化c-Jun的表达正相关,进一步验证了MKK7及JNK/c-Jun通路的信号在胶质母细胞瘤发生发展的中的重要作用,为寻找胶质瘤化疗的新靶点、新化疗药物提供重要的理论依据。
作者贡献:刘特立:文献调研、论文设计及撰写刘 辰:论文设计及修改张羽琪、邓虞娇:文献调研朱华、杨志:论文设计及修改 -
[1] Violet JA, Hofman MS. Prostate-specific membrane antigen from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer[J]. BJU Int, 2017, 120(3): 310-312. doi: 10.1111/bju.13871
[2] 朱华, 程震, 杨志.核医学分子探针在前列腺癌诊断中的临床研究进展[J].中华核医学与分子影像杂志, 2017, 37(2): 103-107. http://d.old.wanfangdata.com.cn/Periodical/zhhyx201702012 Zhu H, Cheng Z, Yang Z. Progress in nuclear molecular probes for noninvasive prostate cancer clinical imaging[J]. Zhonghua He Yi Xue Yu Fen Zi Ying Xiang Za Zhi, 2017, 37(2): 103-107. http://d.old.wanfangdata.com.cn/Periodical/zhhyx201702012
[3] 杨立平, 李福兴, 李文贵. 68Ga-PSMA PET/CT在前列腺癌复发中的应用进展[J].肿瘤防治研究, 2018, 45(7): 505-509. doi: 10.3971/j.issn.1000-8578.2018.17.1689 Yang LP, LI FX, Li WG. Application Progress of 68Ga-PSMA PET/CT in Recurrent Prostate Cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2018, 45(7): 505-509. doi: 10.3971/j.issn.1000-8578.2018.17.1689
[4] Evans JD, Jethwa KR, Ost P, et al. Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease[J]. Pract Radiat Oncol, 2018, 8(1): 28-39. doi: 10.1016/j.prro.2017.07.011
[5] Haffner MC, Kronberger IE, Ross JS, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers[J]. Hum Pathol, 2009, 40(12): 1754-1761. doi: 10.1016/j.humpath.2009.06.003
[6] Stoykow C, Huber-Schumacher S, Almanasreh N, et al. Strong PMSA radioligand uptake by rectal carcinoma: Who put the " S" in PSMA?[J]. Clin Nucl Med, 2017, 42(3): 225-226. doi: 10.1097/RLU.0000000000001484
[7] Hangaard L, Jochumsen MR, Vendelbo MH, et al. Metastases from colorectal cancer avid on 68Ga-PSMA PET/CT[J]. Clin Nucl Med, 2017, 42(7): 532-533. doi: 10.1097/RLU.0000000000001700
[8] Wernicke AG, Varma S, Greenwood EA, et al. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers[J]. APMIS, 2014, 122(6): 482-489. doi: 10.1111/apm.12195
[9] Sathekge M, Lengana T, Modiselle M, et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients[J]. Eur J Nucl Med Mol Imaging, 2016, 44(4): 689-694. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=69845e52518990af0b7199a026b8d015
[10] Nomura N, Pastorino S, Jiang P, et al. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases[J]. Cancer Cell Int, 2014, 14(1): 26-33. doi: 10.1186/1475-2867-14-26
[11] Salas Fragomeni RA, Menke JR, Holdhoff M, et al. Prostate-specific membrane antigen-targeted imaging with [18F]DCFPyL in high-grade gliomas[J]. Clin Nucl Med, 2017, 42(10): e433-e435. doi: 10.1097/RLU.0000000000001769
[12] Sasikumar A, Kashyap R, Joy A, et al. Utility of 68Ga-PSMA-11 PETCT in Imaging of Glioma-A Pilot Study[J]. Clin Nucl Med, 2018, 43(9): e304-e309. doi: 10.1097/RLU.0000000000002175
[13] Moore M, Panjwani S, Mathew R, et al. Well-differentiated thyroid cancer neovasculature expresses prostate-specific membrane antigen-a possible novel therapeutic target[J]. Endocr Pathol, 2017, 28(4): 339-344. doi: 10.1007/s12022-017-9500-9
[14] Bychkov A, Vutrapongwatana U, Tepmongkol S, et al. PSMA expression by microvasculature of thyroid tumors-Potential implications for PSMA theranostics[J]. Sci Rep, 2017, 7(1): 5202-5212. doi: 10.1038/s41598-017-05481-z
[15] Lütje S, Gomez B, Cohnen J, et al. Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68Ga-HBED-CC-PSMA PET/CT [J]. Clin Nucl Med, 2017, 42(1): 20-25. doi: 10.1097/RLU.0000000000001454
[16] Wang HL, Wang SS, Song WH, et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance[J]. PLoS One, 2015, 10(5): e0125924-e0125931. doi: 10.1371/journal.pone.0125924
[17] Schmidt LH, Heitkotter B, Schulze AB, et al. Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer[J]. PLoS One, 2017, 12(10): e0186280-e0186291. doi: 10.1371/journal.pone.0186280
[18] Jochumsen MR, Gormsen LC, Nielsen GL. 68Ga-PSMA avid primary adenocarcinoma of the lung with complementary Low 18F-FDG uptake[J]. Clin Nucl Med, 2018, 43(2): 117-119. doi: 10.1097/RLU.0000000000001935
[19] Han XD, Liu C, Liu F, et al. 64Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model[J]. Oncotarget, 2017, 8(43): 74159-74169. http://d.old.wanfangdata.com.cn/Periodical/tws201906002
[20] Kim SH, Park WS, Park EY, et al. The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry[J]. PLoS One, 2017, 12(6): e0179610-e0179620. doi: 10.1371/journal.pone.0179610
[21] Siva S, Callahan J, Pryor D, et al. Utility of 68Ga prostate specific membrane antigen-positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma[J]. J Med Imaging Radiat Oncol, 2017, 61(3): 372-378. doi: 10.1111/1754-9485.12590
[22] Rowe SP, Gorin MA, Hammers HJ, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT[J]. Ann Nucl Med, 2015, 29(10): 877-882. doi: 10.1007/s12149-015-1017-z
[23] Kesler M, Levine C, Hershkovitz D, et al. 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study[J]. J Nucl Med, 2018. pii: jnumed. 118. 214833. [Epub ahead of print]
[24] Roy SG, Parida GK, Tripathy S, et al. In Vivo Demonstration of PSMA expression in adenocarcinoma urinary bladder using 68Ga-PSMA 11 PET/CT [J]. Clin Nucl Med, 2017, 42(7): 542-543. doi: 10.1097/RLU.0000000000001683
[25] Noto B, Weckesser M, Buerke B, et al. Gastrointestinal stromal tumor showing intense tracer uptake on PSMA PET/CT[J]. Clin Nucl Med, 2017, 42(3): 200-202. doi: 10.1097/RLU.0000000000001491
[26] Sahbai S, Rieping P, Pfannenberg C, et al. Pancreatic ductal adenocarcinoma with high radiotracer uptake in 68Ga-prostate-specific membrane antigen PET/CT[J]. Clin Nucl Med, 2017, 42(9): 717-718. doi: 10.1097/RLU.0000000000001767
[27] Vamadevan S, Le K, Bui C, et al. Prostate-specific membrane antigen uptake in small cleaved B-cell follicular non-hodgkin lymphoma [J]. Clin Nucl Med, 2016, 41(12): 980-981. doi: 10.1097/RLU.0000000000001378
[28] Malik D, Mittal BR, Kumar R, et al. Incidental detection of tracer avidity in liposarcoma on 68Ga-Labeled prostate-specific membrane antigen PET/CT[J]. Clin Nucl Med, 2018, 43(9): e334-e335. doi: 10.1097/RLU.0000000000002189
[29] Gulhane B, Ramsay S, Fong W. 68Ga-PSMA uptake in neurofibromas demonstrated on PET/CT in a patient with neurofibromatosis type 1[J]. Clin Nucl Med, 2017, 42(10): 776-778. doi: 10.1097/RLU.0000000000001777
[30] Vamadevan S, Le K, Shen L, et al. Incidental prostate-specific membrane antigen uptake in a peripheral nerve sheath tumor[J]. Clin Nucl Med, 2017, 42(7): 560-562. doi: 10.1097/RLU.0000000000001686
[31] Gorin MA, Marashdeh W, Ross AE, et al. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi[J]. Nucl Med Commun, 2017, 38(9): 795-798. doi: 10.1097/MNM.0000000000000716
计量
- 文章访问数: 1568
- HTML全文浏览量: 326
- PDF下载量: 611